-
1دورية أكاديمية
المصدر: Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)
مصطلحات موضوعية: Afatinib, Budget Impact, NSCLC, Osimertinib, Uncommon mutation, Medical technology, R855-855.5
وصف الملف: electronic resource
العلاقة: https://journals.aboutscience.eu/index.php/grhta/article/view/2351Test; https://doaj.org/toc/2284-2403Test; https://doaj.org/toc/2283-5733Test
-
2دورية أكاديمية
العنوان البديل: Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations. (English)
المصدر: Global & Regional Health Technology Assessment; Jan-Dec2022, Vol. 9 Issue 1, p22-29, 8p